Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: A meta-analysis

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 3, 2008, Pages 315-319

  Li, J S ^a,b,c   Baker Smith, C M ^b,c   Smith, P B ^a,b,c   Hasselblad, V ^b,c   Murphy, M D ^a   Califf, R M ^b,c   Benjamin Jr , D K ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; BENAZEPRIL; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; VASOACTIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CAUCASIAN; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LOW DRUG DOSE; NATRIURESIS; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SODIUM RETENTION; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION;

ADOLESCENT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHILD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 49949116880     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.113     Document Type: Article

References (17)

1. Li, J.S. et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension 44, 289-293 (2004).
2. Brown, N.J. & Vaughan, D.E. Angiotensin-converting enzyme inhibitors. Circulation 97, 1411-1420 (1998).
3. Ferdinand, K.C. & Armani, A.M. The management of hypertension in African Americans. Crit. Pathw. Cardiol. 6, 67-71 (2007).
4. Cohn, J.N. et al. Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. Am. J. Hypertens. 17, 134-138 (2004).
5. Wells, T. et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J. Clin. Pharmacol. 42, 870-880 (2002).
6. Soffer, B. et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am. J. Hypertens. 10, 795-780 (2003).
7. Menon, S. et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am. Heart J. 152, 394-399 (2006).
8. Brewster, L.M., van Montfrans, G.A. & Kleijnen, J. Systematic review: antihypertensive drug therapy in black patients. Ann. Intern. Med. 141, 614-627 (2004).
9. Woodiwiss, A.J. et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. J. Hypertens. 24, 1057-1064 (2006).
10. Jain, S. et al. Angiotensinogen gene polymorphism at -217 affects basal promoter activity and is associated with hypertension in African-Americans. J. Biol. Chem. 277, 36889-36896 (2002).
11. Veterans Administration Co-operative Study Group of Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br. J. Clin. Pharmacol. 14 (suppl.), 97S-101S (1982).
12. Benjamin, D.K. Jr. et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension 51, 834-840 (2008).
13. U.S. Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies. 〈http://www.fda.gov/cder/ pediatric/Summaryreview.htm〉 (2008). Accessed 9 April 2008.
14. Blumer, J.L. et al. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment. J. Clin. Pharmacol. 43, 128-132 (2003).
15. Wells, T. et al. The pharmacokinetics of enalapril in children and infants with hypertension. J. Clin. Pharmacol. 41, 1064-1074 (2001).
16. Hogg, R.J. et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr. Nephrol. 22, 695-701 (2007).
17. Pasquali, S.K., Sanders, S.P. & Li, J.S. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. Am. Heart J. 144, 608-614 (2002).